Antidepresivi i COVID-19: prikaz slučaja i pregled literature

Marija Dabetić; Milica Nešić; Uroš Dabetić; Milan Latas

doi:10.5937/engrami44-39941

Marija Dabetić
Milica Nešić Clinic for Psychiatry, Clinical Center of Serbia
Uroš Dabetić
Milan Latas

DOI: https://doi.org/10.5937/engrami44-39941

Ključne reči: serotonin, inflamacija, citokini, SSRI, escitalopram, SARS-CoV-2

Sažetak

Uvod. Antiinflamatorno dejstvo antidepresiva nagovešteno je u brojnim istraživanjima i pre pandemije koronavirusa. Aktuelne studije su na velikom broju pacijenata sa simptomatskom COVID-19 infekcijom potvrdile da antidepresivi pokazuju protektivno dejstvo u smislu smanjenja verovatnoće intubacije i smrtnog ishoda. Takođe, odgovor na antidepresive kod osoba sa postkovid depresijom je brži i jači u odnosu na one kod kojih depresija nije vezana za COVID-19. Cilj ovog rada jeste pregled literature vezan za efekat i mehanizme dejstva antidepresiva u COVID-19 infekciji i postkovid sekvelama, dopunjem prikazom tipičnog ambulatnog slučaja pacijentkinje sa post COVID-19 depresivnim poremećajem.

Zaključak. Postkovid depresija je česta sekvela COVID-19 infekcije. SSRI kod post COVID-19 depresije deluju brzo i efikasno, što se može objasniti njihovim antiinflmatornim svojstvima. Blagovremeni skrining i terapija postkovid psihijatrijskih simptoma može značajno umanjiti teret depresije za pojedinca i društvo. Takođe, pandemijska istraživanja stavila su u fokus nove mehanizme dejstva antidepresiva te pružila nove perspektive za sagledavanje etiologije depresije.

Biografije autora

Marija Dabetić

Institut za mentalno zdravlje, Beograd, Srbija

Milica Nešić, Clinic for Psychiatry, Clinical Center of Serbia

Klinika za psihijatriju, Univerzitetski klinički centar Srbije, Beograd, Srbija

Medicinski fakultet, Univerzitet u Beogradu, Beograd, Srbija

Uroš Dabetić

Klinika za ortopedsku hirurgiju i traumatologiju, Univerzitetski klinički centar Srbije, Beograd, Srbija

Milan Latas

Klinika za psihijatriju, Univerzitetski klinički centar Srbije, Beograd, Srbija

Medicinski fakultet, Univerzitet u Beogradu, Beograd, Srbija

Reference

1. Albert PR, Benkelfat C, Descarries L. The neurobiology of depression--revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. Philos Trans R Soc Lond B Biol Sci. 2012 Sep 5;367(1601):2378-81.

2. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 015;49:206-215.

3. Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun. 2020;87:901-909.

4. Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, Salamanca E, Paris N, Daniel C, Gramfort A, Lemaitre G, Bernaux M, Bellamine A, Lemogne C, Airagnes G, Burgun A, Limosin F; AP-HP / Universities / INSERM COVID-19 Research Collaboration and AP-HP COVID CDR Initiative. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021 Sep;26(9):5199-5212.

5. Oskotsky T, Maric I, Tang A, Oskotsky B, Wong RJ, Aghaeepour N, Sirota M, Stevenson DK. Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants. JAMA Netw Open. 2021 Nov 1;4(11):e2133090.

6. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, de Souza Campos VH, Nogueira AMR, de Almeida APFG, Callegari ED, de Figueiredo Neto AD, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Glushchenko AV, Rayner CR, Lenze EJ, Reiersen AM, Guyatt GH, Mills EJ; TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022 Jan;10(1):e42-e51.

7. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri F, Rovere-Querini P; COVID-19 BioB Outpatient Clinic Study group, Benedetti F. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020 Oct;89:594-600.

8. Penninx BWJH. Psychiatric symptoms and cognitive impairment in "Long COVID": the relevance of immunopsychiatry. World Psychiatry. 2021;20(3):357-358.

9. Pavli A, Theodoridou M, Maltezou HC. Post-COVID Syndrome: Incidence, Clinical Spectrum, and Challenges for Primary Healthcare Professionals. Arch Med Res. 2021 Aug;52(6):575-581.

10. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022 Apr;22(4):e102-e107.

11. Anaya JM, Rojas M, Salinas ML, Rodríguez Y, Roa G, Lozano M, Rodríguez-Jiménez M, Montoya N, Zapata E; Post-COVID study group, Monsalve DM, Acosta-Ampudia Y, Ramírez-Santana C. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021 Nov;20(11):102947.

12. Mazza MG, Zanardi R, Palladini M, Rovere-Querini P, Benedetti F. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol. 2022 Jan;54:1-6.

13. Kofod J, Elfving B, Nielsen EH, Mors O, Köhler-Forsberg O. Depression and inflammation: Correlation between changes in inflammatory markers with antidepressant response and long-term prognosis. Eur Neuropsychopharmacol. 2022 Jan;54:116-125.

14. Chamberlain SR, Cavanagh J, de Boer P, Mondelli V, Jones DNC, Drevets WC, Cowen PJ, Harrison NA, Pointon L, Pariante CM, Bullmore ET. Treatment-resistant depression and peripheral C-reactive protein. Br J Psychiatry. 2019 Jan;214(1):11-19.

15. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40:1–7.

16. Köhler CA, Freitas TH, Stubbs B, Maes M, Solmi M, Veronese N, et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol. 2018;55:4195–206.

17. Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, Kley K, Metzendorf M-I, Fischer A-L, Kopp M, Stegemann M, Skoetz N, Fichtner F. Systemic corticosteroids for the treatment of COVID‐19. Cochrane Database of Systematic Reviews 2021, Issue 8. Art. No.: CD014963.

18. Perrin AJ, Horowitz MA, Roelofs J, Zunszain PA, Pariante CM. Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis. Front Psychiatry. 2019 Jun 28;10:423. doi: 10.3389/fpsyt.2019.00423. PMID: 31316402; PMCID: PMC6609575.

19. Budziszewska B, Jaworska-Feil L, Kajta M, Lasoń W. Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism. Br J Pharmacol. 2000 Jul;130(6):1385-93.

20. Carvalho LA, Garner BA, Dew T, Fazakerley H, Pariante CM. Antidepressants, but not antipsychotics, modulate GR function in human whole blood: an insight into molecular mechanisms. Eur Neuropsychopharmacol. 2010 Jun;20(6):379-87.

21. Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N, et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? Biol Psychiatry. (2007) 62:47–54.

22. Hinkelmann K, Moritz S, Botzenhardt J, Muhtz C, Wiedemann K, Kellner M, Otte C. Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: a longitudinal study. Psychoneuroendocrinology. 2012 May;37(5):685-92.

23. McCloskey DJ, Postolache TT, Vittone BJ, Nghiem KL, Monsale JL, Wesley RA, Rick ME. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res. 2008 Mar;151(3):168-72.

24. Roweth HG, Yan R, Bedwani NH, Chauhan A, Fowler N, Watson AH, Malcor JD, Sage SO, Jarvis GE. Citalopram inhibits platelet function independently of SERT-mediated 5-HT transport. Sci Rep. 2018 Feb 22;8(1):3494.

25. Gorog DA, Storey RF, Gurbel PA, Tantry US, Berger JS, Chan MY, Duerschmied D, Smyth SS, Parker WAE, Ajjan RA, Vilahur G, Badimon L, Berg JMT, Cate HT, Peyvandi F, Wang TT, Becker RC. Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat Rev Cardiol. 2022 Jul;19(7):475-495.

26. Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci. 2021 Mar;271(2):249-258.

27. Hoertel N. Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19? JAMA Netw Open. 2021 Nov 1;4(11):e2136510.

28. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2022 Jul 20.